ASSOCIATION BETWEEN REACTIVE OXYGEN SPECIES AND DISEASE-ACTIVITY IN CHRONIC HEPATITIS-C

Reactive Oxygen Species (ROS) may be involved in the damage occurring in the course of chronic HCV infection. Individuals with chronic hepatitis C present increased hepatic levels of malondialdehyde (MDA) and reduced levels of glutathione. To determine whether these observations are associated with serological evidence for ROS injury, MDA and protein carbonyl content (PCC) of serum was determined in 20 HCV positive patients (14 chronic active hepatitis-CAH and 6 cirrhosis) and 20 controls. Compared to controls, HCV positive subjects had increased levels of MDA (13.33 +/- 0.21 SE ng/ml vs. 9.90 +/- 0.65, P < .05) and PCC (4.74 +/- 0.21 nmol/mg vs. 3.68 +/- 0.21, p < .02). Patients with CAH had higher levels than did cirrhotics. Both MDA and PCC correlated with serum ALT levels (r = .792 and r = .818 respectively, p < .001). A common origin for MDA and PCC found in patients with chronic hepatitis C was suggested by the correlation between the two measures (r = .741, p < .001). No correlation were found between MDA or PCC and the hepatic iron content.

These data demonstrate that: (1) lipid and protein oxidation occur in chronic hepatitis C, (2) oxidative damage can be demonstrated as increased serum levels of MDA and PCC, and (3) both MDA and PCC levels correlate with disease activity.

Authors: DH VANTHIEL, OKLAHOMA MED RES FDN, LIVER DIS PROGRAM, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104
Publication: FREE RADICAL BIOLOGY AND MEDICINE 1996; 21(3):291-295

Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Newsletter

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

News and Updates

Anemia and Hepatitis C Treatment
In opposition to what seems logical, research demonstrates that becoming anemic while on Hepatitis C therapy is not such a bad thing.

Bristol-Myers Gains Momentum with All-Oral Hep C Therapy
In a recent study, over one third of previous non-responders cleared Hepatitis C with an interferon-free combo of two Bristol-Myers experimental drugs.

Hepatitis C Gains Access to Brain Cells
Helping to explain why Hepatitis C can cause extrahepatic manifestations (problems outside of the liver), American researchers confirmed that certain brain cells are susceptible to the Hepatitis C virus.